Exacerbation Rate Reduction According to Baseline Blood Eosinophilic Count in Patients with Asthma Treated with ICS/LABA Maintenance and Reliever Therapy

被引：0
|
作者：
Brusselle, G. G. [1 ]
Papi, A. [2 ]
Nicolini, G. [3 ]
Santoro, L. [3 ]
Guastalla, D. [3 ]
机构：
[1] Ghent Univ Hosp, Ghent, Belgium
[2] Univ Ferrara, Ctr Asma, Ferrara, Italy
[3] Chiesi, Parma, Italy
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1294
引用
收藏
页数：2
相关论文
共 33 条
  • [31] Baseline characteristics of patients with severe eosinophilic asthma treated with benralizumab who reduced to anti-inflammatory reliever only vs high-, medium- or low- dose inhaled corticosteroid/formoterol: SHAMAL post-hoc analysis
    Kent, Brian
    Milger-Kneidinger, Katrin
    Heaney, Liam G.
    Menzies-Gow, Andrew
    Shavit, Anat
    Olinger, Lynda
    Jackson, David J.
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [32] Once-Daily Tiotropium Respimat® Add-on to at Least Ics Maintenance Therapy Demonstrates Improved Lung Function in Patients with Symptomatic Asthma, Independent of Serum IgE or Blood Eosinophil Levels
    Tashkin, Donald P.
    Dahl, Ronald
    Virchow, Johann Christian
    Engel, Michael
    Moroni-Zentgraf, Petra
    Zaremba-Pechmann, Liliana
    Kerstjens, Huib A. M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (02) : AB213 - AB213
  • [33] Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial
    Harrison, Tim W.
    Chanez, Pascal
    Menzella, Francesco
    Canonica, Giorgio Walter
    Louis, Renaud
    Cosio, Borja G.
    Lugogo, Njira L.
    Mohan, Arjun
    Burden, Annie
    McDermott, Lawrence
    Garcia Gil, Esther
    Zangrilli, James G.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (03): : 260 - 274
1234